Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial
Eribulin plus gemcitabine is effective and well-tolerated in patients with HER2-negative metastatic breast cancer needing second-line or later treatment, providing a valuable treatment option.
Authors
- Jincai ZHONG
- Yongxia Wang
- Guorong Zou
- Z. Wang (ORCID: https://orcid.org/0009-0000-4306-2373)
- Jie Ouyang
- Mei Xiao (ORCID: https://orcid.org/0000-0002-0373-1023)
- Caiwen Du
- P. Peng
- Xiaolu Xu
- Luzhen Li
- Hong Lin
- Fei Xu
- Jinhui Ye
- Shien Cui
- Gengsheng Yu
- Hong Wang
Institutions
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tung Wah Hospital (CN)
- Panyu Hospital of Chinese Medicine (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Guangdong Provincial Hospital of Traditional Chinese Medicine (CN)
- Zhongshan People's Hospital (CN)
- Fifth Affiliated Hospital of Sun Yat-sen University (CN)
- Dongguan People’s Hospital (CN)
- Traditional Chinese Medicine Hospital of Kunshan (CN)
- Panyu District Central Hospital (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Zhongshan Hospital (CN)
- Weihai Maternal and Child Health Hospital (CN)
- Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine (CN)
- Sun Yat-sen University Cancer Center (CN)
- Jiangmen Central Hospital (CN)
- The First People's Hospital of Zhaoqing (CN)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1038/s43856-026-01483-z
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00